Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early-Phase Clinical Study Evaluating the Safety and Clinical Efficacy of STR-P004 in Subjects With Relapsed/Refractory CD19-Positive Acute Lymphoblastic Leukemia

NCT07245251 is registered in ClinicalTrials.gov with Starna Therapeutics as lead sponsor.

NCT NCT07245251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07245251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early-Phase Clinical Study Evaluating the Safety and Clinical Efficacy of STR-P004 in Subjects With Relapsed/Refractory CD19-Positive Acute Lymphoblastic Leukemia
Lead sponsor
Starna Therapeutics
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 3, 2025
Completion date
December 30, 2026
Enrollment
11 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphobkastic leukemia